A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...